Brothers Michael and Alex Wood share a stem cell bond at the Stadium Stomp – The Advertiser
The Advertiser |
Brothers Michael and Alex Wood share a stem cell bond at the Stadium Stomp
The Advertiser Michael has fought cancer three times since being diagnosed in Year 8, the latest bout helped by a stem cell transplant from brother Alex. Michael, 22, of Redwood Park, was diagnosed with the blood cancer Hodgkin’s lymphoma at age 13. After six rounds … Private clinics’ peddling of unproven stem cell treatments is unsafe and unethicalThe Conversation AU Diabetes alert: Stem Cell Educator therapy is safe and effective for treatmentHindustan Times Standardized Stem CellsHuffPost Guardian (blog) –Business Wire (press release) –eHealth Magazine | Elets all 18 news articles » |
|
J&J turns its back on Capricor and its failed stem cell tech, taking its money and rep with it
Endpoints News A little more than three years ago, J&J stepped up with a $12.5 million upfront to rent a front row seat on Capricor Therapeutics’ $CAPR Phase II stem cell study, looking to see if their off-the-shelf approach could mend a damaged heart. At the time … |
Medical Xpress |
Private clinics’ peddling of unproven stem cell treatments is unsafe and unethical
Medical Xpress Stem cell science is an area of medical research that continues to offer great promise. But as this week’s paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, are exploiting … Brothers Michael and Alex Wood share a stem cell bond at the Stadium StompThe Advertiser Standardized Stem CellsHuffPost Stem cell therapies breaking barriersGuardian (blog) EurekAlert (press release) –Business Wire (press release) –eHealth Magazine | Elets all 18 news articles » |
pharmaphorum |
Oxford BioMedica signs $100m CAR–T deal with Novartis
pharmaphorum The deal represents a major financial boost for the UK biotech firm, which provides bioprocessing services for third parties as well as advancing its own gene and cell therapies. Novartis’ CTL019 could be the first groundbreaking CAR–T to gain approval … Oxford BioMedica and Novartis build on supply deal as CAR–T medication nears finish lineFiercePharma Oxford BioMedica signs major supply deal with NovartisPharmaTimes Oxford BioMedica, Novartis link up on CAR–T drug productionBioPharma Dive |